<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>3-ACETAZOLAMIDE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ACETAZOLAMIDE" rxcui="167">
<ATC code="S01EC01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ACETYLSALICYLIC ACID" rxcui="1191">
<ATC code="A01AD05" />
<ATC code="B01AC06" />
<ATC code="N02BA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the undesirable effects, and especially of metabolic acidosis, of the acetylsalicylic acid in large doses and of the acetazolamide, due to decrease of the elimination of the acetylsalicylic acid by the acetazolamide</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>3-ACETAZOLAMIDE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ACETAZOLAMIDE" rxcui="167">
<ATC code="S01EC01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CARBAMAZEPINE" rxcui="2002">
<ATC code="N03AF01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of carbamazepine with signs of overdose</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT></COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>3-ACETAZOLAMIDE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ACETAZOLAMIDE" rxcui="167">
<ATC code="S01EC01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="LITHIUM" rxcui="6448">
<ATC code="D11AX04" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of lithium with risk of reduction of the therapeutic effectiveness</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT></COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>3-ACETAZOLAMIDE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ACETAZOLAMIDE" rxcui="167">
<ATC code="S01EC01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE" code="N03AG0" /></DRUG2>
<DESCRIPTION>Increase of the hyperammonemia, with incresed risk of encephalopathy</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT></COMMENT>
</INTERACTION>
</INTERACTIONS>
